Fig. 3. TCR^FLT3D/Y cells efficiently target primary AML in mice with high leukemic burden.

a, Schematic overview of the PDX in vivo model with FLT3^D835Y-mutated primary AML cells from patient 7. b, Percentage of human hCD45⁺CD33⁺ cells in PB at baseline (1 d before T cell infusion) and on the indicated days after infusion with TCR^1G4 (n = 6 mice) or TCR^FLT3D/Y (n = 7 mice) cells. Numbers were adjusted for hCD3⁺ T cells. c, Representative flow cytometry plots of viable single BM mononuclear cells (MNCs) from TCR^1G4 (top) and TCR^FLT3D/Y (bottom) cell-treated NSG-SGM3 mice stably engrafted with primary AML FLT3^D/Y cells from patient 7. d, Percentage of hCD45⁺CD33⁺ cells in the BM and spleen at terminal analysis 15 d after T cell infusion. Numbers were adjusted for hCD3⁺ T cells. e, Number of FLT3^D835Y-mutated BM hCD45⁺CD3⁻ cells determined by ddPCR. f,g, Number of mouse (m)CD45⁺ cells in BM (f) and mTCR-β⁺CD8⁺ cells in the BM and spleen (g) at the endpoint. All data are presented as mean ± s.e.m. and were generated from one experiment including six mice treated with TCR^1G4 cells and seven mice treated with TCR^FLT3D/Y cells. Each dot represents one mouse, and statistical analysis was performed with two-tailed Mann–Whitney test. P values are shown, and P < 0.05 was considered statistically significant.

Source data